Given that clinical studies targeting the systemic IL-33 signaling pathway are currently underway in the treatment of COPD (clinicaltrials.gov; NCT04701983; NCT03615040), investigating the role of IL-33 in HLA-DRB1+ RA and lung diseases resulting from airborne exposures may be warranted. Here, IL33 is linked to chronic obstructive pulmonary disease.